Neurovive Pharmaceutical AB, of Stockholm, said board members, other insiders and employees intend to subscribe for a minimum of 129,000 units, equivalent to at least SEK5.4 million (US$555,666) in the company's previously disclosed preferential rights issue with the subscription period between April 18 and May 2.